☰

Cory M. Johannessen, Ph.D. - Publications

Affiliations: 
2008 Harvard University, Cambridge, MA, United States 
Area:
Genetics
Tree Info Grants Similar researchers PubMed Report error

49 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Ito T, Young MJ, Li R, Jain S, Wernitznig A, Krill-Burger JM, Lemke CT, Monducci D, Rodriguez DJ, Chang L, Dutta S, Pal D, Paolella BR, Rothberg MV, Root DE, ... Johannessen CM, et al. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. Nature Genetics. PMID 34857952 DOI: 10.1038/s41588-021-00967-z  0.31
2020 Howard TP, Oberlick EM, Rees MG, Arnoff TE, Pham MN, Brenan L, DoCarmo M, Hong AL, Kugener G, Chou HC, Drosos Y, Mathias KM, Ramos P, Seashore-Ludlow B, Giacomelli AO, ... ... Johannessen CM, et al. Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32631955 DOI: 10.1158/1078-0432.Ccr-19-2717  0.373
2019 Bolan PO, Zviran A, Brenan L, Schiffman JS, Dusaj N, Goodale A, Piccioni F, Johannessen CM, Landau DA. Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization. Cell Systems. PMID 31668800 DOI: 10.1016/J.Cels.2019.10.002  0.317
2019 Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, ... ... Johannessen CM, et al. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. PMID 31543463 DOI: 10.1016/J.Ccell.2019.08.005  0.369
2019 Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, Wei G, Presser AG, Gelbard MK, Zhang W, Zervantonakis IK, ... ... Johannessen CM, et al. Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer. Molecular Cancer Research : McR. PMID 31462500 DOI: 10.1158/1541-7786.Mcr-18-1243  0.387
2019 Togami K, Pastika T, Stephansky J, Ghandi M, Christie AL, Jones KL, Johnson CA, Lindsay RW, Brooks CL, Letai A, Craig JW, Pozdnyakova O, Weinstock DM, Montero J, Aster JC, ... Johannessen CM, et al. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. The Journal of Clinical Investigation. PMID 31437130 DOI: 10.1172/Jci128571  0.352
2019 Bandopadhayay P, Piccioni F, O'Rourke R, Ho P, Gonzalez EM, Buchan G, Qian K, Gionet G, Girard E, Coxon M, Rees MG, Brenan L, Dubois F, Shapira O, Greenwald NF, ... ... Johannessen CM, et al. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nature Communications. 10: 2400. PMID 31160565 DOI: 10.1038/S41467-019-10307-9  0.397
2019 Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, ... ... Johannessen CM, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. PMID 31068700 DOI: 10.1038/S41586-019-1186-3  0.309
2019 Hayes TK, Luo F, Cohen O, Goodale AB, Lee Y, Pantel S, Bagul M, Piccioni F, Root DE, Garraway LA, Meyerson M, Johannessen CM. A functional landscape of resistance to MEK1/2 and CDK4/6 inhibition in NRAS mutant melanoma. Cancer Research. PMID 30819666 DOI: 10.1158/0008-5472.Can-18-2711  0.451
2019 Stover EH, Baco MB, Cohen O, Li Y, Christie E, Bagul M, Goodale A, Lee Y, Pantel S, Rees M, Wei G, Presser A, Zervantonakis I, Bhola P, Ryan J, ... ... Johannessen CM, et al. Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Ap14  0.388
2018 Iniguez AB, Alexe G, Wang EJ, Roti G, Patel S, Chen L, Kitara S, Conway A, Robichaud AL, Stolte B, Bandopadhayay P, Goodale A, Pantel S, Lee Y, Cheff DM, ... ... Johannessen C, et al. Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. Cancer Cell. 34: 922-938.e7. PMID 30537514 DOI: 10.1016/J.Ccell.2018.11.005  0.447
2018 Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, Howard TP, Takeda DY, Ly SH, Kim E, Gannon HS, Hurhula B, Sharpe T, Goodale A, Fritchman B, ... ... Johannessen CM, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nature Genetics. PMID 30224644 DOI: 10.1038/S41588-018-0204-Y  0.392
2018 Konieczkowski DJ, Johannessen CM, Garraway LA. A Convergence-Based Framework for Cancer Drug Resistance. Cancer Cell. 33: 801-815. PMID 29763622 DOI: 10.1016/J.Ccell.2018.03.025  0.413
2018 Guieze R, Liu VM, Rosebrock D, Jourdain A, Hernández-Sánchez M, Martinez Az, Jing S, Baranowski KJ, Thompson PA, Jin-Mi H, Cartun Z, Aygun O, Notarangelo G, Livitz D, Li S, ... ... Johannessen C, et al. Genetic Determinants of Venetoclax Resistance in Lymphoid Malignancies Blood. 132: 893-893. DOI: 10.1182/Blood-2018-99-118604  0.34
2017 Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, ... ... Johannessen CM, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nature Communications. 8: 1324. PMID 29109393 DOI: 10.1038/S41467-017-00965-Y  0.358
2017 Donovan KF, Hegde M, Sullender M, Vaimberg EW, Johannessen CM, Root DE, Doench JG. Creation of Novel Protein Variants with CRISPR/Cas9-Mediated Mutagenesis: Turning a Screening By-Product into a Discovery Tool. Plos One. 12: e0170445. PMID 28118392 DOI: 10.1371/Journal.Pone.0170445  0.359
2017 Stephansky J, Togami K, Ghandi M, Montero J, vonEgypt N, Lindsay R, Brooks C, Aster JC, Johannessen C, Lane AA. Resistance to SL-401 in AML and BPDCN Is Associated with Loss of the Diphthamide Synthesis Pathway Enzyme DPH1 and Is Reversible By Azacitidine Blood. 130: 797-797. DOI: 10.1182/Blood.V130.Suppl_1.797.797  0.343
2017 Wong T, Johannessen C, Fan J, Long H, Liu S, Garraway L. Abstract B15: Comprehensive cistromic characterization of SOX10, a lineage-specific genetic dependency in melanoma, via the integration of functional genomic approaches Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-B15  0.367
2017 Rees MG, Brenan L, Walker A, Johannessen CM. Abstract A18: Predicting synergistic drug combinations from genomic features and single-agent response profiles Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A18  0.324
2017 Cohen O, Kim D, Oh C, Waks A, Oliver N, Helvie K, Marini L, Rotem A, Lloyd M, Stover D, Adalsteinsson V, Freeman S, Ha G, Cibulskis C, Anderka K, ... ... Johannessen C, et al. Abstract S1-01: Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-S1-01  0.366
2017 Bandopadhayay P, Paolella B, O’Rourke R, Ho P, Greenwald N, Sharpira O, Pantel S, Bagul M, Tracy A, Roti G, Balboni A, Vazquez F, Ligon K, Piccioni F, Stegmaier K, ... Johannessen C, et al. TRTH-15. RESISTANCE MECHANISMS TO BET-BROMODOMAIN INHIBITION IN MYC-AMPLIFIED MEDULLOBLASTOMA Neuro-Oncology. 19: iv54-iv55. DOI: 10.1093/Neuonc/Nox083.227  0.357
2017 Johannessen CM, Boehm JS. Progress towards precision functional genomics in cancer Current Opinion in Systems Biology. 2: 74-83. DOI: 10.1016/J.Coisb.2017.02.002  0.358
2016 Brenan L, Andreev A, Cohen O, Pantel S, Kamburov A, Cacchiarelli D, Persky NS, Zhu C, Bagul M, Goetz EM, Burgin AB, Garraway LA, Getz G, Mikkelsen TS, Piccioni F, ... ... Johannessen CM, et al. Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants. Cell Reports. 17: 1171-1183. PMID 27760319 DOI: 10.1016/J.Celrep.2016.09.061  0.485
2016 Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, Fallahi-Sichani M, Dutton-Regester K, Lin JR, Cohen O, Shah P, ... ... Johannessen CM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (New York, N.Y.). 352: 189-196. PMID 27124452 DOI: 10.1126/Science.Aad0501  0.355
2016 Kim JW, Botvinnik OB, Abudayyeh O, Birger C, Rosenbluh J, Shrestha Y, Abazeed ME, Hammerman PS, DiCara D, Konieczkowski DJ, Johannessen CM, Liberzon A, Alizad-Rahvar AR, Alexe G, Aguirre A, et al. Characterizing genomic alterations in cancer by complementary functional associations. Nature Biotechnology. PMID 27088724 DOI: 10.1038/Nbt.3527  0.367
2015 Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, Corsello SM, Capelletti M, Calles A, Butaney M, Sharifnia T, Gabriel SB, Mesirov JP, Hahn WC, Engelman JA, et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 27: 397-408. PMID 25759024 DOI: 10.1016/J.Ccell.2015.02.005  0.382
2015 Johannessen C, Konieczkowski D, Abudayyeh O, Kim JW, Cooper Z, Piris A, Frederick D, Barzily-Rokni M, Straussman R, Haq R, Fisher D, Mesirov J, Hahn W, Flaherty K, Wargo J, et al. Abstract PR04: A melanoma transcriptional state distinction influences sensitivity to MAPK pathway inhibitors Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Pr04  0.47
2015 Wong TC, Johannessen CM, Garraway LA. Abstract B33: Integration of genome-wide datasets identifies SOX10 as a lineage-specific genetic dependency in melanoma Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-B33  0.399
2014 Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discovery. 4: 816-27. PMID 24771846 DOI: 10.1158/2159-8290.Cd-13-0424  0.47
2014 Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discovery. 4: 61-8. PMID 24265154 DOI: 10.1158/2159-8290.Cd-13-0631  0.498
2014 Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, Mckenna A, Cibulskis K, Farlow D, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma Cancer Discovery. 4: 94-109. PMID 24265153 DOI: 10.1158/2159-8290.Cd-13-0617  0.434
2013 Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, Garraway LA. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 504: 138-42. PMID 24185007 DOI: 10.1038/Nature12688  0.51
2013 Wagle N, Allen EMV, Frederick DT, Cooper ZA, Farlow DN, Treacy D, Goetz EM, Johannessen CM, Carter SL, Taylor-Weiner A, Hodis E, Lawrence DP, Sullivan RJ, Getz G, Gabriel SB, et al. Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition. Journal of Clinical Oncology. 31: 9015-9015. DOI: 10.1200/Jco.2013.31.15_Suppl.9015  0.365
2013 Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Flaherty KT, Wargo JA, Root DE, Garraway LA. Abstract PR10: A cyclic AMP-regulated melanocyte lineage program confers resistance to MAP kinase pathway inhibition Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-Pr10  0.498
2012 Wood KC, Konieczkowski DJ, Johannessen CM, Boehm JS, Tamayo P, Botvinnik OB, Mesirov JP, Hahn WC, Root DE, Garraway LA, Sabatini DM. MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. Science Signaling. 5: rs4. PMID 22589389 DOI: 10.1126/Scisignal.2002612  0.388
2012 Johannessen CM, Johnson LA, Lam D, Hamm L, Piccioni F, Root D, Garraway L. Abstract PR5: Identifying mechanisms of drug resistance to MAPK pathway inhibition via genome-scale rescue screens Clinical Cancer Research. 18. DOI: 10.1158/1078-0432.Mechres-Pr5  0.466
2011 Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3085-96. PMID 21383288 DOI: 10.1200/Jco.2010.33.2312  0.482
2011 Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. Abstract 3933: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling Cancer Research. 71: 3933-3933. DOI: 10.1158/1538-7445.Am2011-3933  0.481
2011 Johannessen CM, Boehm J, Hamm L, Yang X, Garraway L. Abstract 1073: A systematic approach to identify the Ras-dependent C-RAF(Ser338)-phosphorylating kinase Cancer Research. 71: 1073-1073. DOI: 10.1158/1538-7445.Am2011-1073  0.404
2010 Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 468: 968-72. PMID 21107320 DOI: 10.1038/Nature09627  0.485
2010 Johannessen CM, Wardwell L, Kim SY, Boehm J, Thomas S, Johnson LA, Hieronymus H, Salehi-Ashtiani K, Hill DE, Zhao JJ, Vidal M, Golub TR, Hahn WC, Garraway LA. Abstract 5769: A novel, high-throughput approach to discovering drug-resistance genes identifies CRAF, CrkL, and TPL2/COT as drivers of resistance to BRAFV600E inhibition Cancer Research. 70: 5769-5769. DOI: 10.1158/1538-7445.Am10-5769  0.441
2010 Barretina J, Caponigro G, Kim S, Stransky N, Venkhatesan K, Reddy V, Berger M, Morrissey M, Morais P, Meltzer J, Thibault J, Mahan S, Sonkin D, Che J, Raman P, ... ... Johannessen C, et al. Abstract 2620: The Cancer Cell Line Encyclopedia project: From integrative cancer genomics to personalized cancer therapy Cancer Research. 70: 2620-2620. DOI: 10.1158/1538-7445.Am10-2620  0.416
2010 Stransky N, Venkhatesan K, Morrissey M, Barretina J, Raman P, Getz G, Berger M, Johannessen C, Callahan A, Morais P, Mahan S, Gupta S, Onofrio R, Sougnez C, Winckler W, et al. Abstract 105: Integrative analysis of genomic and pharmacologic data from the Cancer Cell Line Encyclopedia Cancer Research. 70: 105-105. DOI: 10.1158/1538-7445.Am10-105  0.362
2010 Stransky N, Venkatesan K, Barretina J, Caponigro G, Margolin A, Morrissey M, Raman P, Getz G, Berger M, Johannessen C, Callahan A, Morais P, Mahan S, Gupta S, Onofrio R, et al. Abstract PR4: Integrative analysis of genomic and pharmacologic data from the Cancer Cell Line Encyclopedia Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-Pr4  0.358
2008 Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, Rioth MJ, McClatchey A, Ryeom S, Cichowski K. TORC1 is essential for NF1-associated malignancies. Current Biology : Cb. 18: 56-62. PMID 18164202 DOI: 10.1016/J.Cub.2007.11.066  0.715
2006 Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, Hollstein PE, MacCollin M, Cichowski K. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell. 10: 459-72. PMID 17157787 DOI: 10.1016/J.Ccr.2006.10.003  0.452
2006 DeYoung MP, Johannessen CM, Leong CO, Faquin W, Rocco JW, Ellisen LW. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Research. 66: 9362-8. PMID 17018588 DOI: 10.1158/0008-5472.Can-06-1619  0.336
2005 Sofer A, Lei K, Johannessen CM, Ellisen LW. Regulation of mTOR and cell growth in response to energy stress by REDD1. Molecular and Cellular Biology. 25: 5834-45. PMID 15988001 DOI: 10.1128/Mcb.25.14.5834-5845.2005  0.397
2005 Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proceedings of the National Academy of Sciences of the United States of America. 102: 8573-8. PMID 15937108 DOI: 10.1073/Pnas.0503224102  0.744
Show low-probability matches.